title: [Neuroleptic treatment and neurological soft signs in schizophrenic patients].
abstract: OBJECTIVE
  To appreciate the impact of the neuroleptic treatment on the neurological soft signs (NSS) in schizophrenic patients and to examine their relation with the treatment response based on the level of CGI-improvement.
  
  
  METHODS
  A cross-sectional study bearing on 66 schizophrenic patients: untreated patients (N = 13) and treated patients (N = 53). All patients were assessed by the Krebs et al. Neurological Soft Signs Scale and the Clinical Global Impressions (CGI).
  
  
  RESULTS
  No difference has been noted concerning the NSS total score between treated and untreated schizophrenic patients. Concerning the NSS sub-scores, we have noted a significantly difference in the sensory integration sub-score. In treated patients, no correlation was found between NSS and daily dosage or duration of exposure of neuroleptic treatment, extrapyramidal symptoms and level of CGI-improvement.
  
  
  CONCLUSIONS
  The excess of NSS in schizophrenic patients is independent of the neuroleptic treatment, suggesting that NSS represent a neurodevelopmental risk factor for schizophrenia.
authors.affiliation: Laboratoire de recherche Vulnérabilité aux psychoses, Service de Psychiatrie, hôpital universitaire de Monastir, Monastir, Tunisie. anwar_mec@yahoo.fr
authors.forename: Anwar
authors.initials: A
authors.lastname: Mechri
authors.forename: Héla
authors.initials: H
authors.lastname: Slama
authors.forename: Sabeur
authors.initials: S
authors.lastname: Chebel
authors.forename: Olfa
authors.initials: O
authors.lastname: Mandhouj
authors.forename: Lotfi
authors.initials: L
authors.lastname: Gaha
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003024:Clozapine / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009422:Nervous System Diseases / Q000188:drug therapy / Q000209:etiology*; D010546:Perphenazine / Q000627:therapeutic use; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D010546:Perphenazine; D003024:Clozapine; D006220:Haloperidol; D018967:Risperidone